

France

Tuberculosis profile

Population 2015

64 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.52 (0.49–0.55)	0.8 (0.76–0.85)
Mortality (HIV+TB only)	0.056 (<0.01–0.27)	0.09 (0–0.41)
Incidence (includes HIV+TB)	5.3 (4.7–6)	8.2 (7.2–9.3)
Incidence (HIV+TB only)	0.41 (0.32–0.5)	0.63 (0.49–0.78)
Incidence (MDR/RR-TB)**	0.088 (0.063–0.11)	0.14 (0.1–0.17)

Estimated TB incidence by age and sex (thousands)*, 2015

	0-14 years	> 14 years	Total
Females	0.2 (0.12–0.28)	1.8 (1.3–2.3)	2 (1.5–2.6)
Males	0.2 (0.14–0.26)	3 (2.4–3.7)	3.2 (2.5–4)
Total	0.4 (0.3–0.5)	4.9 (4.5–5.3)	5.3 (4.7–6)

TB case notifications, 2015

Total cases notified	4 788
Total new and relapse	4 494
- % tested with rapid diagnostics at time of diagnosis	0%
- % with known HIV status	
- % pulmonary	73%
- % bacteriologically confirmed among pulmonary	76%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	85% (75–96)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.11 (0.08–0.14)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive		
- on antiretroviral therapy		

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			63 (47–79)
Estimated % of TB cases with MDR/RR-TB	1% (0.65–1.5)	10% (7.1–15)	
% notified tested for rifampicin resistance	71%	126%	4 196
MDR/RR-TB cases tested for resistance to second-line drugs		95	
Laboratory-confirmed cases		MDR/RR-TB: 96, XDR-TB: 9	
Patients started on treatment ****		MDR/RR-TB: 96, XDR-TB: 9	

Treatment success rate and cohort size

	Success	Cohort
New cases registered in 2014		
Previously treated cases registered in 2014		
HIV-positive TB cases, all types, registered in 2014		
MDR/RR-TB cases started on second-line treatment in 2013		
XDR-TB cases started on second-line treatment in 2013		

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2016

National TB budget (US\$ millions)


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence


— Notified (new and relapse)

— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New cases

— Previously treated cases

— HIV-positive — MDR/RR-TB — XDR-TB